IvyRx GLP-1 Review 2026: Flat-Rate Compounded Semaglutide & Tirzepatide at $175–$297/mo

IvyRx offers compounded semaglutide from $175/month and tirzepatide from $275/month with a flat-rate pricing model — your monthly cost stays the same regardless of which dose you're on. That's a genuine differentiator: most compounders charge $100–$150 more per month at higher maintenance doses, so over a full year the flat-rate model can save $600–$1,200 compared to dose-tiered competitors. Where IvyRx falls short is clinical transparency: there's no named medical director on the public website, no disclosed compounding pharmacy, and no required lab work before prescribing. For patients who want to verify who is overseeing their care, those gaps matter. Here's what you need to know as of May 2026.

Quick Verdict

Pricing: The Flat-Rate Advantage

IvyRx keeps pricing simple: one flat monthly rate for each medication, regardless of dose. That structure is rare in the telehealth GLP-1 market, where most platforms charge on a dose-tiered basis — meaning your cost rises from starting dose ($99–$199/mo) to maintenance dose ($299–$449/mo) as you escalate.

For context: Eden Health charges $149 intro then $249/month ongoing for compounded semaglutide, and $249 intro rising to $329/month for tirzepatide. Enhance MD offers $49 first month then $212/month for semaglutide. IvyRx's flat rate lands above the lowest entry points but below where most competitors settle at maintenance dose.

IvyRx accepts HSA/FSA payments and provides an itemized receipt for reimbursement. There is no membership fee separate from the medication cost — one payment covers medication, consultations, and shipping.

Medications Offered

• •Compounded semaglutide (injectable) — standard doses and microdose variants
• •Compounded tirzepatide (injectable) — flat-rate across all dose tiers
• •Microdose GLP-1 program — four-dose packs at $155/month; suited for patients with high GI sensitivity or those re-starting after a pause
• •No brand-name GLP-1s listed — IvyRx is a compounding-only program. If you need FDA-approved Wegovy or Zepbound, you'll need a different provider.

IvyRx's menu is narrower than platforms like Eden Health or Fridays, which also manage brand-name insurance access alongside compounded options. If there's any chance you'll want to switch to brand-name (for insurance coverage, the SELECT cardiovascular indication, or when compounded options narrow further under the FDA 503B exclusion proposal), a provider with both tracks is worth considering.

Clinical Oversight: What's Public vs. What's Missing

IvyRx was founded by a clinical pharmacist and works with licensed US 503A compounding pharmacies. Processing time is typically 2–3 business days. All affiliated providers are described as board-certified US-licensed healthcare professionals.

What IvyRx does NOT publicly disclose:

• •Named medical director — No publicly named physician with verifiable NPI or state license on the About page. This is a transparency gap; reputable platforms like Eden Health and Sprout Health name their medical leadership.
• •Compounding pharmacy partner — The 503A pharmacies used to fill prescriptions are not named on the site. You cannot independently verify PCAB accreditation or LegitScript certification of the specific pharmacy.
• •Required baseline labs — IvyRx does not require bloodwork before prescribing. A responsible compounding program should assess baseline metabolic markers (HbA1c, kidney function) before starting a GLP-1, particularly for patients with undiagnosed type 2 diabetes or contraindications.

How IvyRx Compares to Alternatives

Henry Meds starts at $197/mo for low-dose semaglutide — similar to IvyRx — but scales to $397/mo at the highest dose, while IvyRx stays flat. That's where the flat-rate model delivers real savings for patients who reach higher maintenance doses.

Who IvyRx Is Best For

• •Re-starters: If you've done a GLP-1 program before, had labs done elsewhere, and just want a straightforward flat-rate refill — IvyRx's simple model works
• •High-dose patients: If your provider has already titrated you to a higher dose and you're looking for a lower ongoing cost than your current program, IvyRx's flat rate may undercut competitors by $100+/mo
• •Budget-focused microdosers: The $155/month microdose program is one of the lower entry points in the market for patients who need a gradual start
• •NOT recommended for first-time GLP-1 patients: Without required labs or a named medical director, the clinical safety net is thinner than what's standard at higher-rated providers. Use our match quiz to find a better-vetted starting point.

Verdict

IvyRx's flat-rate pricing is legitimately differentiated — it's one of the few compounders that won't increase your monthly bill as your dose escalates. For cost-savvy patients who are already experienced with compounded GLP-1s, it's worth comparing directly against your current program.

The transparency gaps are real, though. A provider that doesn't publicly name its medical director or compounding pharmacy is asking patients to take more on trust than the alternatives require. If you're starting GLP-1 therapy for the first time, we recommend prioritizing a provider that requires baseline labs and discloses their clinical leadership. Eden Health ($249/mo, named medical director, required labs, Katalys-tracked) and Enhance MD ($212/mo ongoing, $49 first month) are better-vetted alternatives at similar price points.

Use our cost calculator to run the flat-rate math against your current program over 12 months, or take the match quiz to find the best-fit provider for your clinical situation and budget.

Medical disclaimer: This review is for informational purposes only and does not constitute medical advice. Compounded GLP-1 medications are not FDA-approved finished pharmaceutical products. Compounded semaglutide is subject to legal status changes as FDA enforcement evolves — see our compounding ban guide for the latest. Never start, stop, or change a GLP-1 medication without consulting a licensed healthcare provider.

Sources